Copper as diagnostic marker of cancers

Background - There is suggestive evidence of familial clustering of breast and prostate cancer in first-degree relatives; women with a family history of prostate cancer are at increased risk of breast cancer. Few studies have investigated joint family history of breast and prostate cancer and prostate cancer risk, and no study to date has examined lethal prostate cancer. Methods - We studied 42,672 from the Health Professionals Follow-up Study between 1996 to 2012. During follow-up, 4,258 prostate cancer cases were diagnosed, of whom 380 were lethal disease. Men self-reported family history of breast and prostate cancer, including in siblings or parents. Using cause-specific hazards regression, we estimated hazard ratios (HR) and 95% confidence intervals (CI) of the association between family history and prostate cancer risk and progression. Results - About 8% of men had a family history of prostate cancer, 8.7% had a family history of breast cancer, and 1.4% of men had a family history of both breast and prostate cancer. A family history of prostate cancer was significantly associated with an increased risk of prostate cancer (HR: 1.69; 95% CI: 1.54-1.85). Increased risk was higher for men with a father diagnosed with prostate cancer (HR: 1.64 95% CI: 1.49-1.80) than for men with a diagnosis in a brother(s) (HR: 1.51 95% CI: 1.27-1.80). A positive family history of breast cancer was associated with a small, but significant 22% increased risk (HR: 1.22; 95% CI: 1.11-1.35). Familial breast cancer in a sister (HR: 1.22 95% CI: 1.06-1.41) increased risk more than familial breast cancer in a mother (HR: 1.12; 95% CI: 0.99-1.25). Men with a family history of both prostate and breast cancer had a 52% (HR: 1.52; 95%CI: 1.23-1.88) increased risk of prostate cancer compared to men with no family history of either cancer. Risk of lethal prostate cancer was also significantly increased for men with a positive family history of prostate cancer (HR: 1.64; 95% CI: 1.20-2.24), as well as for men with a family history of breast cancer (HR: 1.47; 95% CI: 1.07-2.01). Conclusions - These results support the findings of familial aggregation of breast and prostate cancer, and for the first time suggest an association between familial breast cancer and lethal prostate cancer. Data from this prospective study have translational relevance for family counseling of cancer patients. Citation Format: Lauren E. Barber, Travis A. Gerke, Sarah C. Markt, Giovanni Parmigiani, Lorelei A. Mucci. A family affair: Prostate cancer risk and family history of breast or prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2543.

The aim of the study is identification of correlations between the serum concentrations of iron and the risk of breast cancer among female BRCA1 mutations carriers and unselected breast cancer patients. The first group (99 triplet) selected for the trial were Polish women, positive for at least one of three founder mutations in BRCA1 gene dominating in Poland (5382insC, C61G, 4153delA). Serum was collected at the time of breast cancer diagnosis. Persons with detected tumor were considered as cases and the others were considered as controls. One case and two controls were paired regarding many criteria (e.g. age, family cancer history, cigarettes smoking, adnexectomy status ) to achieve the maximum of similarity between them. The subjects of the second group (28 triplet) selected for the trial were Polish women, positive for at least one of three founder mutations in BRCA1 gene. Serum was collected 1-2 years before breast cancer diagnosis. One case and two controls were matched for year of birth, past history of cancer, adnexectomy status and cigarettes smoking to achieve the maximum of similarity between them. The subjects of the third group were unselected cancer for the trial were Polish women. Serum was collected during breast cancer diagnosis before treatment. One case and one control were matched for year of birth (+/- 3 years), number and location of cancer among Io relatives, smoking-the number of pack years (+/- 10%), adnexectomy status, CHEK2 mutation. The proportion of cases and control in the first quartile was taken as a reference to calculate the odds ratio, confidence interval and p-value of the multivariate conditional logistic regression. The iron was quantitatively measured by ICP-MS (Inductively Coupled Plasma Mass Spectrometry), (model Elan DRC-e 6100 th, PerkinElmer). This study shows that concentration levels of iron in blood serum are a strong factors associated with an additionally increased risk of breast cancer among BRCA1 mutation carriers and unselected breast cancer patients. For iron concentration in BRCA1 carriers (serum collected at the time of breast cancer diagnosis) all quartiles above the first one had a decreased risk of breast cancer. The results are shown in Table ​Table11. Table 1 Association between Fe serum concentration and risk of breast cancer in BRCA 1 carriers (serum collected at the time of breast cancer diagnosis). For iron concentration in BRCA1 carriers (serum collected 1-2 years before breast cancer diagnosis) the last quartile had a decreased risk of breast cancer. The results are shown in Table ​Table22. Table 2 Association between Fe serum concentration and risk of breast cancer in BRCA 1 carriers (serum collected 1-2 years before breast cancer diagnosis). Individuals classified in the III and IV quartile had lower risk of breast cancer however results were statistically insignificant. The strongest result and lowest cancer risk was for Fe > 1350 μg/l (OR= 0,289, p= 0,0426) For iron concentration in unselected breast cancer patients (serum was collected during breast cancer diagnosis before treatment) all quartiles were statistically insignificant. The results are shown in Table ​Table33. Table 3 Association between Fe serum concentration and risk of breast cancer Individuals classified in the III quartile had lower risk of breast cancer however results were statistically insignificant. The strongest result and lowest cancer risk was for Fe > 1000 μg/l (OR= 0,6698, p= 0,25554). For iron concentration in unselected breast cancer patients (serum was collected during breast cancer diagnosis before treatment) before 55 years old, third quartile had a decreased risk of breast cancer. The results are shown in Table ​Table44. Table 4 Association between Fe serum concentration and risk of cancer in group of patients < 55 years old. Individuals classified in the III quartile had lower risk of breast cancer (OR=0,248, p=0,019); The strongest result and lowest cancer risk was for Fe concentration higher than 987 μg/l (III quartile) ; max 1285 μg/l (III quartile)

Breast and ovarian cancers belong to the most common malignancies diagnosed in women. The major inherited susceptibilities to breast and ovarian cancers are germline mutations in either BRCA1 or BRCA2 which however, explain only small number of breast and ovarian cancer cases. Data suggest that majority breast and ovarian cancers are caused by low or moderate penetrance gene mutations. Identification of such mutations provides cancer risk assessment and will help in prophylactic, early diagnosis and treatment. In 2005 three international multidisciplinary consortia have been initiated: Breast Cancer Association Consortium (BCAC), Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and Ovarian Cancer Association Consortium (OCAC) which are forums of investigators from centers over the world, including International Hereditary Cancer Center in Szczecin. The aim of these consortia’s is to combine data from many studies, to provide a reliable assessment of the breast and ovarian cancer risks associated with different genetic and environmental factors, and to identify potential modifiers of cancer risk in carriers of BRCA1 and BRCA2 mutation. BCAC includes 54 centers (table ​(table1)1) over the world and focuses on identification of genes associated with breast cancer risk. Table 1 Centers collaborating in BCAC Currently, BCAC database includs demographic, clinical and epidemiological data from 73,000 breast cancer patients and 80,000 unaffected women. Up to now, 125 genetic alterations (SNPs) localized in different genes have been examined. These SNPs have been selected based on its positive association with breast cancer risk detected in preliminary analyses or Genome-Wide Association Study (GWAS). Results have been presented in 12 manuscripts published in high impact journals, e.g. J Natl Cancer Inst, Nature and Nat Genet (http://www.srl.cam.ac.uk/consortia/bcac/pubs/pubs.html). Ten SNPs have been found to be associated with breast cancer risk overall or by clinical and pathological characteristics (table ​(table22). Table 2 BCAC SNPs associated with breast cancer risk overall or by clinical and pathological characteristics CIMBA database contains demographic, clinical and epidemiological data from 15,700 BRCA1 and 8,600 BRCA2, mutation carriers including 12,700 breast cancer patients, 2,500 ovarian cancer patients and 9,100 unaffected patients from 42 centers over the world (table ​(table33). Table 3 Centers collaborating in CIMBA Results have been presented in 9 manuscripts published in high impact journals, e.g. Am. J Hum Genet, Hum Mol Genet (http://www.srl.cam.ac.uk/consortia/cimba/pubs/pubs.html). Six SNPs have been found to be associated with breast cancer risk (table ​(table44). Table 4 SNPs associated with breast cancer risk in BRCA1/2 carriers OCAC includes 24 centers over the world and focuses on identification of genes that may be related to the risk of ovarian cancer (table ​(table55). Table 5 Centers collaborating in OCAC Currently, OCAC database includs demographic, clinical and epidemiological data from 22,000 ovarian cancer patients and 18,000 unaffected women. Several genetic alterations (SNPs) localized in different genes have been examined. Results have been presented in 13 manuscripts published in high impact journals, e.g. Nat Genet, Cancer Res, In J Cancer (http://www.srl.cam.ac.uk/consortia/ocac/pubs/pubs.html). Seven SNPs have been found to be associated with ovarian cancer risk overall or by clinical and pathological characteristics (table ​(table66). Table 6 SNPs associated with ovarian cancer risk

Introduction: Women with dense breast tissue face a two-fold higher risk of breast cancer, yet mammography sensitivity is as low as 30% in this group, underscoring the need for more sensitive and accessible screening methods. Liquid-based biopsies for early breast cancer detection are emerging but currently remain out of reach for clinical use. Recent data on nucleotide assessment from plasma in breast cancer have been mixed with 87% sensitivity for late-stage disease (stage 3-4) but only 20% sensitivity for early-stage disease (stage 1-2). Proteomics is an exciting area for early cancer screening where improvements in sample preparation and equipment have enabled major advances in early cancer detection. This is particularly true for a deep proteome assay as the detection of proteins 8-9 orders of magnitude lower in abundance than common plasma proteins can be identified. Objective: This study evaluates the presence of breast cancer using label-free shotgun mass spectrometry-based proteomics on less than 1 ml of plasma in &amp;gt;1,100 women classified as either healthy or as newly diagnosed breast cancer patients with a focus on early-stage disease (stages 0-2). Methods: 363 banked blood samples from multiple sources were used to establish a training set consisting of 156 stage 0-4 treatment-naive breast cancer patients, 46 benign breast conditions, and 161 healthy controls. Samples were age and demographic matched between healthy, benign, and breast cancer cohorts. Samples were processed in a blinded manner using an automated and novel deep proteomic platform developed by Astrin Biosciences. This platform combines label-free quantitative mass spectrometry and a proprietary breast cancer-specific spectral library to extract features used to train a classifier to identify breast cancer patients. Blinded validation of this AI classifier was evaluated on the remaining 788 patient samples (healthy, n=374; benign, n=81; breast cancer, n=333) to confirm performance characteristics. Results: Preliminary analyses from our training set of deep proteomic profiling identified over 8,600 proteins in total and up to 7,500 proteins per patient (median 6,926 proteins) with a dynamic range spanning over 8 orders of magnitude. Differentially expressed proteins in early-stage breast cancer patients from healthy patient controls were also observed. Our AI classifier, using a leave-one-out cross-validation (LOOCV) approach on the interim cohort, separated healthy controls from breast cancer patients with an ROC of &amp;gt;95% and a specificity and sensitivity greater than 85% across all stages. Conclusion: We have developed a highly sensitive blood-based assay that utilizes deep proteomic profiling to identify distinctive cancer specific signatures in women who are undergoing screening for breast cancer. This work enables us to develop a protein-based classifier from plasma for early detection of breast cancer. Impact on screening strategies: This assay advances clinical diagnostics by identifying proteomic markers for early detection of breast cancer. This innovative approach enhances screening strategies for women with dense breasts who are at average or high-risk based on family history, specific genetic mutations such as BRCA1/2, race, or other factors. Acknowledgements: We thank all of the members at Astrin Biosciences who have contributed endless hours dedicated to ending cancer. We are also grateful to all the donors who generously contributed blood samples to this study. Citation Format: A. Horrmann, Y. Travadi, G. Schaap, K. Mallery, K. J. Kamalanathan, N. Bristow, C. Galeano-Garces, S. Y. Bae, A. Hesch, C. Rungkittikhun, B. R. Konety, J. M. Drake. Deep Proteomics and AI Classifier for Early Breast Cancer Detection [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD5-03.

Additional age-related issues should be considered when managing breast cancer in young women.1 Among them, the potential consequences of anticancer treatments on ovarian function and fertility potential are of particular concern and need to be addressed as early as possible after diagnosis.2,3 Therefore, current guidelines strongly voice the need to provide proper oncofertility counseling with all patients of reproductive age with newly diagnosed cancer irrespective of its stage.2,3 This is a crucial step to discuss with all young women their disease and prognosis, the required treatments including their potential gonadotoxicity, the need for contraception during and after active systemic therapies, their future desire of conception, likelihood of pregnancy, its safety and outcomes as well as the available strategies to avoid the negative impact of the proposed treatment on ovarian function and fertility.

Evidence suggests that the risk of breast and prostate cancer is increased among those with a family history of the same disease and particularly among first-degree relatives. However, less is known about the relationship between breast and prostate cancer within families and particularly among minority populations. Analyses of participants in the Women's Health Initiative observational cohort who were free of breast cancer at the time of their baseline examination were conducted. Subjects were followed for breast cancer through August 31, 2009. A Cox proportional hazards regression modeling approach was used to estimate the risk of breast cancer associated with a family history of prostate cancer, breast cancer, and both among first-degree relatives. There were 78,171 eligible participants, and 3506 breast cancer cases were diagnosed during the study period. A family history of prostate cancer was associated with a modest increase in breast cancer risk after adjustments for confounders (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 1.02-1.26). In a separate analysis examining the joint impact of both cancers, a family history of both breast and prostate cancer was associated with a 78% increase in breast cancer risk (aHR, 1.78; 95% CI, 1.45-2.19). Risk estimates associated with a family history of both breast and prostate cancer were higher among African American women (aHR, 2.34; 95% CI, 1.09-5.02) versus white women (aHR, 1.66; 95% CI, 1.33-2.08). These findings suggest that prostate cancer diagnosed among first-degree family members increases a woman's risk of developing breast cancer. Future studies are needed to determine the relative contributions of genes and a shared environment to the risk for both cancers.

Soy foods have been part of traditional Asian diets for many centuries, while soy products were introduced in Western countries only a few decades ago. Migrants from Asia maintained their food habits to a certain degree when they moved to the U.S., but they also adopted Western foods (1). Inspired by studies among migrants and by the low incidence rates for several cancers among Asians, research into the protective effects of isoflavones in soy foods was initiated. Due to their estrogen-like structure, much of the research has focused on hormone-dependent cancers, i.e., breast, endometrial, ovarian, and prostate cancer, but some work on colorectal cancer has also been performed. During years of experimental and epidemiologic research, it has become evident that not all populations may derive the same benefit from consuming soy foods. One of the more consistent findings in soy research is the fact that epidemiologic studies report a stronger protective effect of soy foods against breast cancer among women who grew up in Asian countries and in those who consumed soy foods throughout childhood and adolescence (2). This presentation will focus on epidemiologic studies that have investigated the association between soy foods and cancer risk among populations with different ethnic backgrounds. In addition, some underlying mechanisms that may be responsible for ethnic differences, such as intestinal equol production, genetic polymorphisms, and timing of exposure will be discussed. Epidemiologic studies among women of Asian, primarily Japanese and Chinese, ancestry show a more consistent protective effect against breast cancer than investigations among Western populations; the odds ratio (OR) was 0.71 (95% CI: 0.60-0.85) among Asians when the highest and lowest intake group were compared, while soy food was unrelated to breast cancer risk in Western studies (OR = 1.04; 95%CI: 0.97-1.11) (2). Similarly, a meta-analysis of prostate cancer studies found a lower risk associated with soy consumption only among Asian (OR = 0.52; 95%CI: 0.33-0.81) but not Western populations (OR = 0.99; 95% CI: 0.85-1.16) (3). On the other hand, meta-analyses for endometrial, ovarian, and colorectal cancer described only small differences in associations by ethnicity (4, 5). Recent case-control analyses nested within the Multiethnic Cohort in Hawaii and Los Angeles examined urinary isoflavone excretion as a biomarker of soy intake and reported similar results for breast but not prostate cancer. While the risk associated with breast cancer was 0.69 (95% CI: 0.51-0.92) among Japanese Americans and 0.98 (95% CI: 0.61-1.55) among Caucasians (6), the risk estimates did not differ by ethnicity for prostate cancer (7). Evidence from observational and intervention studies also suggests possible differential effects of soy intake on biomarkers of breast cancer risk (8-10), e.g., mammographic density and concentrations of serum estrogens and testosterone, urinary estrogen metabolite patterns, IGF-I, and PSA. Whereas the higher intake and possibly the type of soy foods in Asian populations may explain the observations for breast and prostate cancer risk (11), bioavailability of bioactive substances may also be a contributing factor (12). For example, the capacity of the intestinal bacteria to metabolize the isoflavone dadzein into the metabolite equol varies across populations and may confer a greater protection against disease than the other isoflavonoids (13, 14). Another reason that not all individuals may benefit from soy food exposure to the same degree is genetic variation. Genetic polymorphisms may alter enzyme activity or modulate the expression of genes involved in pathways influenced by isoflavones and relevant to cancer risk. Menopausal status, obesity, and other dietary components are other causes for isoflavones to exert differential actions across populations. Alternatively, the overall effect of soy foods on carcinogenesis may depend on the time of life when isoflavones were administered because isoflavones have estrogenic and anti-estrogenic effects. A number of case-control studies that assessed soy intake during childhood or adolescence found a stronger protection for early life than adult soy intake. Since experimental studies indicate that estrogen exposure in young animals induces protection against cancer development, the weak estrogenic effects of isoflavones in soy beans, if consumed early in life, may achieve or accelerate differentiation of breast tissue structures similar to an early pregnancy and, thereby, make the tissue less susceptible to carcinogens and prevent tumor development later in life. Since the reports about beneficial effects of soy against cancer come primarily from Asian populations who have consumed soy foods since childhood and whose diet and lifestyle differs in many other ways from Western countries, the expectations of individuals in Western countries who start eating soy products later in life may not be fulfilled. Therefore, future research in different populations should focus on how soy affects cancer risk throughout life.

Background: Clinical germline genetic testing of cancer predisposition gene panels is used to identify women at increased risk for breast cancer. The identification of pathogenic mutations in established high and moderate predisposition genes may result in improved risk management of breast cancer for tested patients and their family members through tailored screening, prophylactic surgeries, or chemoprevention. However, the risks of breast cancer associated with mutations in these genes have likely been overestimated for many women in the general population because previous studies have focused on individuals with a family history of breast and/or ovarian cancer, early onset disease, or triple negative breast cancer. The goal of the “CAnceR RIsk Estimates Related to Susceptibility” (CARRIERS) study is to estimate breast cancer risks associated with mutations in hereditary cancer panel genes in the general population. Methods: Germline DNA samples from blood or saliva were obtained from 39,439 breast cancer patients and matched unaffected controls from six US-based cohorts (BWHS, CPSII, CTS, MEC, NHS1, NHS2, WHI). DNA was subjected to dual bar-coded QIAseq multiplex PCR-based amplification of 1733 target regions covering all coding regions of 37 cancer predisposition genes and sequenced. Mutation calling was conducted with Haplotype Caller and Vardict. Results: High quality sequence data was obtained for 38,990 of 39,439 samples (98.9%) and for 99.3% of target regions. Pathogenic mutations in 12 known breast cancer predisposition genes were identified 4.5% of all breast cancer cases and 2.1% of controls; and in 6.7% of African American breast cancer cases and 1.8% of controls. Differences in mutation frequencies were observed by age with mutations in 7.8% of cases diagnosed £50 years of age and 4.0% of cases diagnosed over age 50. Mutations in ATM, BRCA1, BRCA2, and PALB2 were enriched 2 to 3-fold in cases diagnosed under age 50 relative to older cases. No change in frequency of CHEK2 mutations by age was observed. In case-control analyses mutations in BRCA1, BRCA2 and PALB2 were significantly associated with a high risk of breast cancer (odds ratio (OR)&amp;gt;4.0). Of these, BRCA1 and BRCA2 displayed ORs of 13.5 and 16.6 in the £50 age group, but only 5.7 and 3.2 in the &amp;gt;50 age group. Only minor age-specific effects were observed for PALB2. Mutations in ATM and CHEK2 were associated with moderate risks of breast cancer (OR=2.0 to 4.0) in the younger age group, but not in the older age group. Conclusions: Results from the CARRIERS cohort-based study establish that mutations in known breast cancer predisposition genes are associated with only moderate risks of breast cancer in the general population. However, risks are substantially increased for BRCA1 and BRCA2 but not ATM, CHEK2 or PALB2 mutations in those £50 years of age. The age-related estimates of breast cancer risk for each of the hereditary cancer panel genes in this study may inform selection of individuals in the general population who may benefit from genetic testing and associated risk management strategies. Citation Format: Couch FJ, Hu C, Hart SN, Gnanaolivu RD, Lilyquist J, Lee KY, Gao C, Eckloff B, Samara R, Klebba J, Auer P, Bernstein L, Gaudet M, Haiman C, Palmer JR, Yao S, Domchek SM, Weitzel JN, Goldgar DE, Nathanson KL, Kraft P, Polley EC. Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS2-01.

Background: To ascertain the contribution of germline alterations in BRCA1 and BRCA2 in an unselected cohort of Asian breast cancer patients and healthy controls. Methods: Two thousand five hundred and ninety-two invasive breast cancer patients and 2,815 healthy controls were included into our study. Amplicon-based targeted sequencing of exonic and proximal splice site junction regions of 31 known and probable breast cancer susceptibility genes were performed on Fluidigm Access Array system, with sequencing conducted on Illumina HiSeq2500 platform. Variant calling was performed as per GATK recommended best practices and were validated with Sanger sequencing. Results: Comparable BRCA1 and BRCA2 carrier rates were observed among breast cancer patients with frequencies of 57 (2.2%) and 66 (2.5%), respectively. Both BRCA1 and BRCA2 conferred increased breast cancer risk with odds ratio 13.0 (95% Cl: 5.2–32.4) and 12.5 (95% Cl: 5.4–28.9), respectively. BRCA1/2 carriers were more likely to be younger, have family history of breast and/or ovarian cancer, have higher grade tumours and for BRCA1 carriers, they were more likely to have hormone receptor negative breast cancers. Notably, 45.7% of breast cancer patients fulfilled the NCCN guidelines for recommendation for genetic counselling and genetic testing, and of these, 80% of BRCA1/2 carriers fulfilled the NCCN guidelines. Conclusion: Taken together, our results show that approximately 5% of unselected Asian breast cancer patients are carriers of germline BRCA1 / 2 mutations. Our study could provide a framework for genetic breast cancer risk assessment and calibration, and enable risk assessment and management of Asian breast cancer patients attending

BackgroundRelevant studies suggest that serum vitamin level is related to the risk of breast cancer, and dietary pattern and drug supplementation can significantly affect the level of vitamin in the body. Therefore, intervention of vitamin level in the body is expected to be a potential strategy to reduce the risk of breast cancer. However, the current epidemiological findings of serum vitamin levels and breast cancer risk are inconsistent, and the relationship between serum vitamin and breast cancer is still controversial. In this study, we compared the serum vitamin expression levels of healthy people, benign breast patients, and breast cancer patients, and evaluated the relationship between B vitamin levels and breast cancer risk.MethodsThe study used liquid chromatography-tandem mass spectrometry to determine the serum vitamin levels of 520 people who attended Yunnan Cancer Hospital from September 2020 to December 2020. After screening by exclusion criteria, 38 patients with benign breast diseases, 87 patients with breast cancer and 91 healthy controls were finally included. The kruskal–wallis H test was used to compare the differences in serum vitamin levels of subjects. Χ2 test was used to evaluate the relationship between B vitamin level and age,BMI,TNM staging,Ki-67,Her-2,surgery and chemotherapy, and other baseline characteristics and through binary logistic regression analysis, calculating odds ratio and 95% confidence interval (CI) to evaluate the relationship between B vitamins and breast cancer risk.ConclusionThe levels of VitB1 and VitB5 in the serum of breast cancer patients and patients with benign breast diseases were higher than those in the healthy control group, while the expression levels of VitB3 in breast cancer patients were lower than those in the healthy control group and the breast benign disease groups. The level of VitB1 was positively correlated with breast cancer risk. The VitB3 level was negatively correlated with breast cancer risk. The VitB5 level is not significantly related to the risk of breast cancer.

Does a young woman living with a smoker or taking a job working in a smoky bar have a greater chance of developing breast cancer? Some scientists believe that such situations can indeed raise a woman’s risk of developing breast cancer before the age of 50. Because epidemiological and toxicological studies show that women’s breast tissue may be especially sensitive to exposure to carcinogens prior to first pregnancy, these researchers contend that public education should be directed at alerting adolescents and young women to the potential risk. However, not everyone in the international public health community agrees that the evidence to date supports a link between passive smoking and breast cancer, and some say that women are being alarmed unnecessarily. This disagreement has sparked debate that is sometimes heated. The stakes are high because breast cancer is the most common cancer in women in industrialized countries, according to the WHO. It is the leading cancer killer of nonsmoking women, and second only to lung cancer deaths among women who smoke. Among the researchers interviewed for this article who disagree that there is enough evidence to link secondhand smoke (SHS) with breast cancer, the majority call the evidence to date “suggestive but not sufficient,” as the Surgeon General’s 2006 report, The Health Consequences of Involuntary Exposure to Tobacco Smoke, put it. That characterization is based largely on the fact that the research considered when the Surgeon General’s report was being amassed did not clearly link even active smoking to breast cancer. Researchers in this camp do, however, stress that ongoing campaigns to prohibit smoking in public will protect the whole of society against the wide variety of ills proven to be caused by SHS. These include lung cancer, cardiovascular disease, and sudden infant death syndrome, among others. A smaller group contends that the question of whether or not SHS causes breast cancer is a political issue with the potential to compromise the scientific process. “A premature decision about causality could jeopardize the credibility of the entire review process and all of the other, established effects of secondhand smoke,” says Michael Thun, national vice president of epidemiology and surveillance research for the American Cancer Society. Adds Valerie Beral, director of the University of Oxford Cancer Research UK Epidemiology Unit, “To prematurely come to conclusions about the causation when there is a big division in the scientific community . . . is bad science.” Thun debated the subject in a series of public forums held in conjunction with scientific meetings. Taking the opposing view was Kenneth C. Johnson, a research scientist with the Public Health Agency of Canada, who was one of the first scientists to discern a potential link. During the debates, Johnson pointed out there are about the same number of studies linking breast cancer to passive smoking as there were linking lung cancer to SHS in 1986, when the Surgeon General concluded that passive smoking caused lung cancer. Johnson also says that more of the breast cancer studies are statistically significant, and that the estimated risk for breast cancer is higher.

eP061: Genetic risk for breast and ovarian cancer in a diverse and unselected population

To the Editor, Breast-Cancer Risk in Families with Mutations in PALB2: A.C. Antoniou, S. Casadei, T. Heikkinen, et al. N Engl J Med. 2014;371:497-506. In a study published in N Engl J Med. August 2014, researchers from 14 centers in eight countries investigated information from 362 family members from 154 families who had an abnormal partner and localizer of BRCA2 (PALB2) gene, but did not have an abnormal BRCA1 or BRCA2 gene. Their aim was to demonstrate the importance of loss-of-function mutations in PALB2 as a cause of hereditary breast cancer. The study included 311 women with an abnormal PALB2 gene; 229 of these women had been diagnosed with breast cancer and 51 men with an abnormal PALB2 gene; seven of whom had been diagnosed with breast cancer. The researchers compared the breast cancer risk of the study population to the general population. They found out that overall, women with an abnormal PALB2 gene had a risk of breast cancer that was 9.47 times higher than average. Women with an abnormal PALB2 gene had a 14% risk of developing breast cancer by age 50 and a 35% risk of developing breast cancer by age 70. The average lifetime risk of breast cancer is about 12%. This increase in risk linked to an abnormal PALB2 gene was dependent on the women’s age and family history. They have demonstrated that the relative risk of breast cancer among PALB2 mutation carriers increased significantly as birth cohort became more recent (P<0.001). In women with an abnormal PALB2 gene, breast cancer risk was eight to nine times higher than average in women aged 20 to 39, six to eight times higher than average in women aged 40 to 60, and five times higher than average in women older than 60 years of age. By the age of 70, women with an abnormal PALB2 gene with no family history of breast cancer had a 33% risk of developing breast cancer whereas women with two or more first-degree relatives with breast cancer at 50 years of age had a 58% risk of developing the disease. The authors concluded that based on their estimates, breast cancer risk for a PALB2 mutation carrier, even in the absence of a family history of breast cancer, would be classified as high according to various guidelines. The researchers also reported that this level of risk may justify adding PALB2 to genetic testing for BRCA1 and BRCA2. A Genetic counselor’s perspective Partner and localizer of BRCA2 (PALB) is a gene whose protein facilitates the function of BRCA2 and interacts with BRCA1 to aid in repairing double strand and interstrand cross-link DNA damage. Biallelic PALB2 mutations cause Fanconi Anemia complement group N (FANCN) and monoallellic mutations in the PALB2 gene are associated with increased breast and pancreas cancer risks (1). PALB2 mutations may account for as much as 3% of familial breast cancer risk (2). A recent study of 362 members from PALB2 mutation positive families found that the risk for breast cancer in female mutation carriers ranged between 33% to 58% by age 70, with the higher risks relating to those women with a family history of early onset (<50) breast cancer in 2 first degree family members (3). The study also identified an 8 fold increase in male breast cancer risk and a 2 fold increase in ovarian cancer risk, both of which need to be confirmed in additional studies due a lack of statistical significance. These data suggest that female PALB2 mutation carriers may have breast cancer risks that are similar to those conferred by mutations in the BRCA2 gene. These findings suggest that women who carry PALB2 gene mutations may warrant similar breast cancer screening and prevention strategies as those offered to BRCA2 mutation carriers. PALB2 mutation analysis is available and is rapidly being adopted into clinical practice. As the data continues to accumulate it is likely that PALB2 mutation analysis will become a standard part of genetic testing in the realm of hereditary breast cancer predisposition. Whether testing will be done in addition to BRCA1/2 or as part of a larger breast cancer gene panel remains to be determined. In addition, more data will provide evidence to support the development of specific management guidelines to aid in the care of these at risk patients.

Association between preoperative serum vitamin D and high-density lipoprotein-cholesterol levels and effects on breast cancer prognosis

Unraveling Genes, Hormones, and Breast Cancer